Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials

Publish date:: October 20, 2020

Key clinical point: There are very limited data from phase 3 trials to judge racial differences in response to therapies for psoriasis.

Major finding: Of psoriasis trials with ethnoracial data, 85.8% of participants were White, 19.5% were Hispanic, 9.2% were Asian, and 3.1% were black.

Data source: A cross-sectional analysis of the clinicaltrials.gov database.

Disclosures: The research had no funding source. Three of the nine authors reported financial relationships with pharmaceutical companies.

Citation:

Reddy VD et al. Br J Dermatol. 2020 Sep 17. doi: 10.1111/bjd.19468.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Psoriatic Arthritis

Osteoporosis prevalence in PsA similar to general population,

Synovial, skin gene expression differences may explain PsA treatment responses,

Tildrakizumab for psoriasis shows durable efficacy over 5 years,

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials,

Guselkumab improvements for psoriatic arthritis persist through 1 year,